Based on the information in the press release you provided, Protalix BioTherapeutics (PLX) is simply announcing that it will release its second‑quarter 2025 financial and business results on August 14, 2025 and will host a conference call/webcast at 8:30 a.m. EDT. The release does not contain any statements about revised fiscal‑year guidance, updated revenue or profit forecasts, or any other outlook for the remainder of 2025.
Therefore, the company did not provide any revised guidance or outlook for the rest of 2025 in this particular announcement. If you need that information, you will have to wait for the actual Q2 2025 results (which are scheduled for August 14) or check subsequent communications that might include updated guidance.
Other Questions About This News
Did the company address any changes in manufacturing capacity or cost structure that could affect margins?
Were there any unexpected one‑time items or non‑recurring expenses that influenced the quarter's results?
Are there any updates on the progress of key clinical trials or regulatory submissions mentioned in the call?
How does Protalix's performance this quarter compare to its main competitors in the recombinant therapeutic protein space?
What were the actual Q2 2025 revenue and earnings figures, and how do they compare to analyst expectations?
Did the management discuss any strategic initiatives, such as M&A or asset divestitures, that could alter the company's growth trajectory?
What is the market's reaction to the earnings release and conference call, and what short‑term price movement can be expected?
How does the reported cash flow and balance sheet strength affect the company's runway and potential for future capital raises?
What were the details of any new partnership or licensing agreements announced, and how might they impact future revenue streams?